Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | LDLR | P01130 | 1/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19329904 | 0.92 | KDM4E (0.46) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| Acetic Acid SCHEMBL19329768 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| SCHEMBL19330017 | 0.85 | HIF1A (0.50) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| SCHEMBL19329940 | 0.84 | ALDH1A1 (0.44) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| SCHEMBL19329913 | 0.83 | BCHE (0.50) | ALDH1A1KDM4ESMN1; SMN2TDP1LDLR | |
| SCHEMBL19329935 | 0.80 | ADRB2 (0.52) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| Acetic Acid SCHEMBL19330042 | 0.78 | KDM4E (0.66) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| SCHEMBL19329931 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| Acetic Acid SCHEMBL20819252 | 0.75 | ALDH1A1 (0.46) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A | |
| Acetic Acid SCHEMBL20915051 | 0.74 | ADRB2 (0.50) | ALDH1A1KDM4EHIF1ASMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | ADRB2 229/4885ALDH1A1 1292/4885KDM4E 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.